A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2008
This article has no abstract
Epistemonikos ID: 92eca1284d05e7e38eaaff88e991520d8fd29ace
First added on: Jan 21, 2025